KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 99 filers reported holding KEROS THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $48,289,720 | -20.7% | 1,514,734 | 0.0% | 1.03% | -7.0% |
| Q2 2023 | $60,862,012 | -15.1% | 1,514,734 | -9.8% | 1.10% | -21.7% |
| Q1 2023 | $71,711,106 | -11.1% | 1,679,417 | 0.0% | 1.41% | -8.7% |
| Q4 2022 | $80,645,604 | +27.6% | 1,679,417 | 0.0% | 1.54% | +31.5% |
| Q3 2022 | $63,180,000 | +36.2% | 1,679,417 | 0.0% | 1.17% | +39.5% |
| Q2 2022 | $46,402,000 | -49.2% | 1,679,417 | 0.0% | 0.84% | -43.2% |
| Q1 2022 | $91,327,000 | -7.1% | 1,679,417 | 0.0% | 1.48% | +17.3% |
| Q4 2021 | $98,263,000 | +47.9% | 1,679,417 | 0.0% | 1.26% | +73.0% |
| Q3 2021 | $66,438,000 | -6.9% | 1,679,417 | 0.0% | 0.73% | +1.2% |
| Q2 2021 | $71,325,000 | -31.0% | 1,679,417 | 0.0% | 0.72% | -25.4% |
| Q1 2021 | $103,368,000 | -12.7% | 1,679,417 | 0.0% | 0.97% | -6.8% |
| Q4 2020 | $118,466,000 | +82.9% | 1,679,417 | 0.0% | 1.04% | +27.4% |
| Q3 2020 | $64,775,000 | +2.8% | 1,679,417 | 0.0% | 0.81% | -8.2% |
| Q2 2020 | $62,995,000 | – | 1,679,417 | – | 0.89% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 396,911 | $21,584,000 | 5.10% |
| Deep Track Capital, LP | 1,380,306 | $75,061,000 | 4.81% |
| Opaleye Management Inc. | 265,750 | $14,451,000 | 4.49% |
| Octagon Capital Advisors LP | 340,214 | $18,501,000 | 4.00% |
| First Light Asset Management, LLC | 658,145 | $35,790,000 | 3.16% |
| Altium Capital Management LP | 126,000 | $6,852,000 | 2.29% |
| Nantahala Capital Management | 816,830 | $44,419,000 | 1.96% |
| Orbimed Advisors | 1,679,417 | $91,327,000 | 1.48% |
| CHI Advisors LLC | 62,229 | $3,384,000 | 1.44% |
| Parkman Healthcare Partners LLC | 72,690 | $3,953,000 | 1.16% |